CHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDD

Abstract

Article1 October 1960CHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDDDELBERT M. BERGENSTAL, M.D., F.A.C.P., ROY HERTZ, M.D., F.A.C.P., MORTIMER B. LIPSETT, M.D., RICHARD H. MOY, M.D.DELBERT M. BERGENSTAL, M.D., F.A.C.P.Search for more papers by this author, ROY HERTZ, M.D., F.A.C.P.Search for more papers by this author, MORTIMER B. LIPSETT, M.D.Search for more papers by this author, RICHARD H. MOY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-53-4-672 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOur approach to the chemotherapy of adrenocortical carcinoma is based upon the original observations of Nelson and Woodard.1 They observed that the oral administration to dogs of the insecticide, DDD, or Rothane, induced a selective necrosis of the zona fasciculata and zona reticularis of the adrenal cortex. Nichols and his associates2, 3 pursued this finding and demonstrated that adrenal cortical function was markedly diminished in dogs so treated. However, early attempts to apply this adrenocorticolytic effect in man were unsuccessful.4, 5, 6Further exploration of the therapeutic potential of this compound was made possible by the observations that a contaminant...Bibliography1. NelsonWoodard AAG: Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1-dichloroethane (DDD or TDE), Arch. Path. 48: 387, 1949. Google Scholar2. NicholsGardner JLI: Production of insulin sensitivity with the adrenocorticolytic drug DDD (2,2-bis(parachlorophenyl)-1, dichloroethane), J. Lab. and Clin. Med. 37: 229, 1951. MedlineGoogle Scholar3. NicholsGreen JHD: Effect of DDD therapy on metabolic response of dogs to ACTH injection, Am. J. Physiol. 176: 374, 1954. CrossrefMedlineGoogle Scholar4. SheehanSummersNichols HLVKJ: DDD therapy in Cushing's syndrome, Lancet 1: 312, 1953. CrossrefMedlineGoogle Scholar5. Tornblom N: Administration of DDD to diabetics with hyaline changes and hyperpolysaccharidemia, Acta med. scandinav. 154: 83, 1956. CrossrefMedlineGoogle Scholar6. ZimmermanBlockWilliamsHitchcockHoelocher BHWWLCRB: The effects of DDD (1,1-dichloro-2,2 bis (p-chlorophenyl) ethane) on the human adrenal: attempts to use an adrenal destructive agent in the treatment of disseminated mammary and prostatic cancer, Cancer 9: 940, 1956. CrossrefMedlineGoogle Scholar7. NicholsHennigar JGR: Studies on DDD, 2,2-bis (parachlorophenyl)-1,1-dichloroethane, Exper. Med. and Surg. 15: 310, 1957. MedlineGoogle Scholar8. CuetoBrown CJH: The chemical fractionation of an adrenocorticolytic drug, Endocrinology 62: 226, 1958. CrossrefGoogle Scholar9. CuetoBrown CJH: Biological studies on an adrenocorticolytic agent and the isolation of the active components, Endocrinology 62: 334, 1958. CrossrefMedlineGoogle Scholar10. BergenstalLipsettMoyHertz DMMBRR: Regression of adrenal cancer and suppression of adrenal function in man by o,p′DDD, Tr. A. Am. Physicians 72: 341, 1959. Google Scholar11. BergenstalLipsettMoyHertz DMMBRHR: Biological activities of steroids in relation to cancer, 1960, Academic Press, New York. Google Scholar12. WerbinOng HS: Improved colorimetric determination of urinary 17-ketosteroids, Anal. Chem. 26: 762, 1956. CrossrefGoogle Scholar13. SilberPorter RHCC: The determination of 17,21-dehydroxy-20-ketosteroids in urine and plasma, J. Biol. Chem. 210: 923, 1954. CrossrefMedlineGoogle Scholar14. BursteinLieberman SS: Hydrolysis of ketosteroid hydrogen sulfates by solvolysis procedures, J. Biol. Chem. 233: 331, 1958. CrossrefMedlineGoogle Scholar15. HertzBergenstalLubsJackson RDMHASJ: Observations on adrenal carcinoma with special reference to the effects of amphenone, Cancer 10: 765, 1957. CrossrefMedlineGoogle Scholar16. Moy RH: Unpublished data. Google Scholar17. VilarTullner OWW: Effects of o,p′DDD on histology and 17-hydroxycorticosteroids output of the dog adrenal cortex, Endocrinology 65: 80, 1959. CrossrefMedlineGoogle Scholar18. Tullner WW: Functional and structural recovery of the dog adrenal cortex after DDD treatment, Program of the Forty-second meeting of the Endocrine Society, Miami, 1960, p. 93. Google Scholar19. TullnerHertz WWR: Effect of intravenous o,p′DDD on plasma 17-hydroxycorticoid secretion in the dog, Endocrinology 66: 494, 1960. CrossrefGoogle Scholar20. Von Oettingen WF: The halogenated aliphatic, olefinic, cyclic, aromatic, and aliphaticaromatic hydrocarbons including the halogenated insecticides, their toxicity and potential changes, U. S. Government Printing Office, Washington, D. C., 1955, p. 347. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DELBERT M. BERGENSTAL, M.D., F.A.C.P.; ROY HERTZ, M.D., F.A.C.P.; MORTIMER B. LIPSETT, M.D.; RICHARD H. MOY, M.D.Affiliations: Bethesda, Maryland*Received fo